Third Harmonic Bio Inc. Cash Flow Conversion Efficiency
Third Harmonic Bio Inc. cash flow conversion efficiency. Based on the latest financial reports, Third Harmonic Bio Inc. (THRD) has a cash flow conversion efficiency ratio of -0.049x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.48 Million) by net assets ($272.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Third Harmonic Bio Inc. (2020–2024)
Cash flow conversion efficiency of Third Harmonic Bio Inc. from 2020 to 2024. This chart illustrates how Third Harmonic Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Third Harmonic Bio Inc. (THRD) stock price for real-time trading data and today's change.
Third Harmonic Bio Inc. Cash Flow Conversion Ratio Explained
Third Harmonic Bio Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Third Harmonic Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Third Harmonic Bio Inc. ranked by their cash flow conversion efficiency. Also see Third Harmonic Bio Inc. (THRD) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trigold Holdings Ltd
TWO:3709
|
-0.318x |
|
Eisen- und Hüttenwerke AG
F:EIS
|
-0.010x |
|
J&V Energy Tech Co Ltd
TW:6869
|
-0.009x |
|
VT GMP Co.Ltd
KQ:018290
|
-0.043x |
|
ODFJELL TECHNOLOGYLTD
F:ND4
|
0.302x |
|
Hainan Yedao Group Co Ltd
SHG:600238
|
-0.076x |
|
Guangdong Tengen Industrial Group C
SHE:003003
|
0.025x |
|
Jahwa Electron
KO:033240
|
0.032x |
Annual Cash Flow Conversion Efficiency for Third Harmonic Bio Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Third Harmonic Bio Inc. from 2020 to 2024. Review THRD FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $285.15 Million | $-34.50 Million | -0.121x | -59.41% |
| 2023-12-31 | $269.08 Million | $-20.43 Million | -0.076x | +37.16% |
| 2022-12-31 | $289.07 Million | $-34.92 Million | -0.121x | -135.83% |
| 2021-12-31 | $-46.71 Million | $-15.75 Million | 0.337x | -32.64% |
| 2020-12-31 | $-18.36 Million | $-9.19 Million | 0.500x | -- |
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more